Innovating Works

KAN

Desconocido
TOBeATPAIN: Targeting neuroinflammation to combat pathological pain in neurodegenerative diseases and chronic pa... KANCERA AB participó en un H2020: H2020-MSCA-ITN-2017 Damage to the central (CNS) and peripheral (PNS) nervous systems causes altered perception of pain (pathological pain) which is a common fea...
2018-07-05 - 2022-07-31 | Financiado
SYNTRAIN: Targeting SYNthetic lethal interactions for new cancer treatments TRAINing network KANCERA AB participó en un H2020: H2020-MSCA-ITN-2016 Breast and ovarian cancer constitute serious health challenges in the EU. To identify new improved cancer therapeutic approaches, we will pu...
2016-08-10 - 2020-11-30 | Financiado
A-PARADDISE: Anti Parasitic Drug Discovery in Epigenetics KANCERA AB participó en un FP7: This proposal builds on the proven methodology developed in the SEtTReND FP7 project to develop inhibitors of schistosome HME as lead compou...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.